GeneDx Holdings Corp (WGS)
19.61
-0.78
(-3.83%)
USD |
NASDAQ |
May 31, 16:00
19.66
+0.05
(+0.25%)
After-Hours: 20:00
GeneDx Holdings Research and Development Expense (Quarterly): 11.57M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.57M |
| December 31, 2023 | 12.25M |
| September 30, 2023 | 14.29M |
| June 30, 2023 | 17.14M |
| March 31, 2023 | 14.59M |
| December 31, 2022 | 24.37M |
| September 30, 2022 | 13.35M |
| June 30, 2022 | 27.17M |
| Date | Value |
|---|---|
| March 31, 2022 | 21.32M |
| December 31, 2021 | 22.25M |
| September 30, 2021 | 17.83M |
| June 30, 2021 | 11.95M |
| March 31, 2021 | 53.13M |
| December 31, 2020 | 31.16M |
| September 30, 2020 | 19.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.57M
Minimum
Mar 2024
53.13M
Maximum
Mar 2021
20.76M
Average
17.83M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| GE HealthCare Technologies Inc | 324.00M |
| Spok Holdings Inc | 2.951M |
| Ontrak Inc | 1.078M |
| DarioHealth Corp | 6.642M |
| FOXO Technologies Inc | 0.283M |